Results 31 to 40 of about 13,617 (225)

Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China

World Allergy Organization Journal, 2022
Background: Omalizumab is an effective treatment for chronic spontaneous urticaria (CSU) patients aged ≥12 years, but its efficacy in patients aged
Ao Wang, MD, Yuhui Yun, MM, Zhihua Wen, MM, Yingxia Gao, BS, Shuzhen Qi, MD, Yu Zhang, MD, Yunsheng Liang, MD, Xu Yao, MD   +7 more
doaj   +1 more source

Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience [PDF]

, 2016
Chronic urticaria is a condition characterized by the appearance of wheals and/or angioedema that last for at least 6 weeks. According to the recent recommendations, if H1-antihistamines used in four times licensed doses remain ineffective, add-on ...
Joanna Dawicka, Aleksandra Wilkowska, Roman Nowicki, Elżbieta Grubska-Suchanek   +3 more
core   +1 more source

Omalizumab and IgE in the Control of Severe Allergic Asthma

Frontiers in Pharmacology, 2022
Omalizumab, a human immunoglobulin (Ig)G1 antibody against IgE, is a therapeutic agent for bronchial asthma. The Global Initiative for Asthma guidelines indicate that the use of omalizumab should be considered as an option in step 5 of treatment for ...
Yasuhiro Gon, Shuichiro Maruoka, Kenji Mizumura   +2 more
doaj   +1 more source

Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid. [PDF]

, 2019
Recent studies suggest an important role of immunoglobulin E (IgE) as an alternative pathogenic pathway in the development of bullous pemphigoid (BP), as the most frequent subepidermal blistering disease of the skin Use of IgE targeted therapies, such as
Gadaldi, Karolina, Borradori, Luca, Schlapbach, Christoph, Feldmeyer, Laurence, Jafari, Morteza, Yawalkar, Nikhil   +5 more
core   +1 more source

Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3+Tregs

, 2021
IgE-FcεR1 cross-linking on human pDCs impairs their capacity to generate regulatory T-cells and in vitro omalizumab restores this ability. These findings may pave the way for novel biomarkers to assess omalizumab clinical efficacy and responder patients ...
López Abente, Jacobo, Palomares Gracia, Óscar, Benito Villalvilla, Cristina, Jaumont, Xavier, Pfister, Pascal, Tassinari, Paolo   +5 more
core   +1 more source

Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients. [PDF]

, 2017
BACKGROUND Omalizumab has been shown to be effective in treating chronic spontaneous urticaria (CSU). The reduction in FcεRI receptor density on the surface of basophils and mast cells is thought to play a major role in its effectiveness. We conducted
S. Reichenbach, Jörg, Lukas, Hausmann, O, Pecaric-Petkovic, T, Pichler, W, T. Pecaric-Petkovic, O. Stalder, W. Pichler, M. Coslovsky, Reichenbach, S, Coslovsky, M, Stalder, O, L. Jörg, O. Hausmann   +13 more
core   +1 more source

Omalizumab and other biologics in drug desensitization [PDF]

, 2020
Purpose of review; Omalizumab has been proposed for controlling adverse reactions during drug desensitization. Our aim is to know the current evidence involving the use of omalizumab in drug-allergy desensitization.
Blanca-López, Natalia, Fernández, Javier, Javier Fernandez, Ruano-Zaragoza, María, María Ruano-Zaragoza, Natalia Blanca-Lopez   +5 more
core   +1 more source

A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad

Monaldi Archives for Chest Disease, 2020
Omalizumab proved to be very effective in improving control of severe atopic asthma. Many small-sized studies suggested a potential role for omalizumab in the management of aspirin-exacerbated respiratory disease. The aim of this study is to describe the
Paolo Cameli, Miriana d'Alessandro, Laura Bergantini, Elena Silvestri, Arianna Romaldi, Giacomo Emmi, Paola Parronchi, Elena Bargagli   +7 more
doaj   +1 more source

Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes

Acta Dermato-Venereologica
Solar urticaria is a rare photodermatosis with several unknown pathogenic, clinical and therapeutic aspects. This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management ...
David Pesqué, Andrea Ciudad, Evelyn Andrades, Dulce Soto, Ramon Gimeno, Ramon M. Pujol, Ana M. Giménez-Arnau   +6 more
doaj   +1 more source

Smoldering Systemic Mastocytosis Without Detectable KIT Mutation: A Debilitating Course and Therapeutic Challenge

Cancer Nexus, EarlyView.
Graphical abstract illustrating the clinical course and treatment response. ABSTRACT Systemic mastocytosis (SM) is a clonal hematologic neoplasm driven by activating KIT mutations, particularly D816V. Indolent SM typically follows a stable course, progression to higher‐burden subtypes is uncommon.
Homeniuk Anna, Medina Esenbekova, Micheal Bishara, Layo Akinrinwoye, Leila Metellus, Joane Titus   +5 more
wiley   +1 more source